trending Market Intelligence /marketintelligence/en/news-insights/trending/3LG6LVYN7DZ2pXgbTvX3mg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Report: WuXi Biologics prices HK$3.98B IPO

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Report: WuXi Biologics prices HK$3.98B IPO

China-based WuXi Biologics (Cayman) Inc. priced its IPO at the top end of its guidance, Reuters reported, citing a source.

The company priced the issue of 193 million shares at HK$20.60 apiece to raise about HK$3.98 billion.

WuXi provides a comprehensive, integrated and customized range of services for the discovery, development and manufacturing of biologics.